|
|
|
|
| LEADER |
07223nam a2200889 i 4500 |
| 001 |
22074 |
| 003 |
CtWfDGI |
| 005 |
20150728142005.0 |
| 006 |
m o d |
| 007 |
cr zn||||uuuuu |
| 008 |
130731t20122012enkad ob 001 0 eng d |
| 020 |
# |
# |
|z 9781845939434 (alk. paper)
|
| 040 |
# |
# |
|a CtWfDGI
|b eng
|c CtWfDGI
|e rda
|
| 050 |
1 |
4 |
|a RM267
|b .A554 2012eb
|
| 082 |
0 |
4 |
|a 615.7/92
|2 23
|
| 245 |
0 |
0 |
|a Antimicrobial drug discovery :
|b emerging strategies /
|c edited by George Tegos, University of New Mexico, Department of Pathology, Center for Molecular Discovery, University of New Mexico Health Sciences, Albuquerque, USA and Eleftherios Mylonakis, Harvard Medical School, Massachusetts General Hospital, Division of Infectious Diseases, Boston, USA.
|
| 264 |
# |
1 |
|a Wallingford, Oxfordshire, UK :
|b CABI,
|c 2012.
|
| 264 |
# |
4 |
|c Ã2012
|
| 300 |
# |
# |
|a 1 online resource (x, 357 pages) :
|b illustrations, charts.
|
| 336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
| 337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
| 338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
# |
|a Advances in molecular and cellular microbiology ;
|v 22
|
| 504 |
# |
# |
|a Includes bibliographical references and index.
|
| 505 |
0 |
# |
|a Emerging discovery strategies : an evolving necessity / Anthony R. Ball and George P. Tegos -- The antibiotic crisis / Arnold L. Demain and Jaroslav Spizek -- Structure, genetic regulation, physiology and function of the AcrAB-TolC efflux pump of escerichia coli and salmonella / Leonard Amaral ... [et al.] -- Small molecule efflux pump inhibitors from natural products as a potential source of antimicrobial agents / Sanjay M. Jachak ... [et al.] -- Fungal efflux-mediated resistance : from targets to inhibitors / Brian C. Monk ... [et al.] -- Vacuolar ATPase (V-ATPase) : a model proton pump for antifungal drug discovery -- Karlett J Parra -- Drug tolerance, persister cells and drug discovery / Kim Lewis -- Inhibition of quorum sensing as a novel antimicrobial strategy -- Gilles Brackman, Hans J. Nelis and Tom Coenye -- Filamentous temperature-sensitive mutant Z (FtsZ) protein as an antibacterial target / Jaroslaw M. Boberek ... [et al.] -- Lysostaphin : a silver bullet for staph / John F. Kokai-Kun -- Strategies to identify modified ribosomally synthesized antimicrobials -- Alan J. Marsh ... [et al.] -- QSAR based discovery of antimicrobial peptides active against multidrug resistant bacteria / Christopher D. Fjell ... [et al.] -- Acetyl-CoA carboxylase as a target for antibacterial development / Grover L. Waldrop -- Underexploited targets in LPS biogenenesis for the design of antibacterials / Laura Cipolla ... [et al.] -- Predicting and dissecting biomolecular interactions by information-driven docking / Panagiotis Kastritsis & Alexandre M.J.J Bonvin -- Anti-fungals and anti-fungal drug discovery / Richard Calderone ... [et al.] -- Pathosystematic studies and the rational design of antifungal interventions / Elaine M Bignell and Darius Armstrong-James -- In vivo high-throughput antimicrobial discovery screens utilizing caenorhabditis elegans as an alternative host / Jeffrey J. Coleman and Eleftherios Mylonakis -- Drosophila melanogaster as a versatile model for discovery of drugs effective against human microbe-induced infection and pathology / Yiorgos Apidianakis and Dimitrios P. Kontoyiannis -- Antimicrobial photosensitizers - harnessing the power of light to treat infections / Sulbha K Sharma, Tianhong Dai and Michael R Hamblin -- Nanoparticle platforms for antimicrobial therapy / David Trofa, Joshua D. Nosanchuk -- Antimicrobial activity of carbon nanotubes / Shaobin Liu, Yuan Chen.
|
| 506 |
# |
# |
|a Access limited to subscribing institution.
|
| 520 |
3 |
# |
|a This book, inclusive of 22 chapters, describes novel approaches currently used for antimicrobial drug discovery, focusing on agents for use against bacterial and fungal pathogens. Specific chapters discuss: (1) concepts relevant to drug resistance; (2) microbial mechanisms related to efflux pumps and studies on their potential inhibitors; (3) impact of multidrug tolerance of biofilms and persister cells; (4) bacterial quorum-sensing inhibition; (5) inhibition of the bacterial filamentous temperature-sensitive mutant Z (FtsZ); (6) antibacterial properties of lysostaphin; (7) strategies to identify modified ribosomally synthesized antimicrobials; (8) quantitative structure-activity relationship studies of novel antimicrobial peptides; (9) bacterial acetyl-CoA carboxylase and lipopolysacharide as drug targets for antibiotic development; (10) pathosystematic systems biology for the rational design of novel antifungal compounds; (11) specific animal models for novel antimicrobial discovery; and (12) new antimicrobial technology platforms such as antimicrobial photodynamic therapy and carbon nanotubes.
|
| 530 |
# |
# |
|a Also available in print format.
|
| 588 |
# |
# |
|a Title from PDF title page (viewed July 31, 2013).
|
| 650 |
# |
0 |
|a Anti-infective agents
|x Development.
|
| 650 |
# |
0 |
|a Drug development.
|
| 650 |
# |
0 |
|a Drug resistance.
|
| 650 |
1 |
2 |
|a Anti-Infective Agents
|x pharmacology.
|
| 650 |
1 |
2 |
|a Drug Design.
|
| 650 |
2 |
2 |
|a Disease Models, Animal.
|
| 650 |
2 |
2 |
|a High-Throughput Screening Assays
|x methods.
|
| 650 |
2 |
2 |
|a Photosensitizing Agents
|x pharmacology.
|
| 650 |
# |
4 |
|a Prion, Viral, Bacterial and Fungal Pathogens of Humans, (New March 2000)
|
| 650 |
# |
4 |
|a Animal Models of Human Diseases, (New March 2000)
|
| 650 |
# |
4 |
|a Animal and in vitro Models for Pharmaceuticals, (New March 2000)
|
| 650 |
# |
4 |
|a Non-drug Therapy and Prophylaxis of Humans, (New March 2000)
|
| 650 |
# |
4 |
|a Biosensors and Biological Nanotechnology, (New June 2002)
|
| 650 |
# |
4 |
|a Biochemistry and Physiology of Microorganisms, (New March 2000)
|
| 650 |
# |
7 |
|a Bacteria.
|2 cabt
|
| 650 |
# |
7 |
|a Fungi.
|2 cabt
|
| 650 |
# |
7 |
|a Acetyl-CoA carboxylase.
|2 cabt
|
| 650 |
# |
7 |
|a Animal models.
|2 cabt
|
| 650 |
# |
7 |
|a Antibacterial agents.
|2 cabt
|
| 650 |
# |
7 |
|a Antifungal agents.
|2 cabt
|
| 650 |
# |
7 |
|a Bacterial diseases.
|2 cabt
|
| 650 |
# |
7 |
|a Biofilms.
|2 cabt
|
| 650 |
# |
7 |
|a Disease models.
|2 cabt
|
| 650 |
# |
7 |
|a Drug development.
|2 cabt
|
| 650 |
# |
7 |
|a Drug resistance.
|2 cabt
|
| 650 |
# |
7 |
|a Drug susceptibility.
|2 cabt
|
| 650 |
# |
7 |
|a Drug targets.
|2 cabt
|
| 650 |
# |
7 |
|a Human diseases.
|2 cabt
|
| 650 |
# |
7 |
|a Laboratory animals.
|2 cabt
|
| 650 |
# |
7 |
|a Lipopolysaccharides.
|2 cabt
|
| 650 |
# |
7 |
|a Mycoses.
|2 cabt
|
| 650 |
# |
7 |
|a Peptide antibiotics.
|2 cabt
|
| 650 |
# |
7 |
|a Phototherapy.
|2 cabt
|
| 650 |
# |
7 |
|a Resistance mechanisms.
|2 cabt
|
| 650 |
# |
7 |
|a Structure activity relationships.
|2 cabt
|
| 655 |
# |
0 |
|a Electronic books.
|
| 690 |
# |
# |
|a VV210
|
| 690 |
# |
# |
|a VV400
|
| 690 |
# |
# |
|a VV450
|
| 690 |
# |
# |
|a VV710
|
| 690 |
# |
# |
|a WW900
|
| 690 |
# |
# |
|a ZZ394
|
| 700 |
1 |
# |
|a Tegos, George,
|e editor of compilation.
|
| 700 |
1 |
# |
|a Mylonakis, Eleftherios,
|e editor of compilation.
|
| 710 |
2 |
# |
|a C.A.B. International,
|e issuing body.
|
| 776 |
0 |
8 |
|d Wallingford, Oxfordshire : CABI, c2012.
|i Print version:
|t Antimicrobial drug discovery.
|w (DLC)2012001019
|z 9781845939434
|
| 830 |
# |
0 |
|a Advances in molecular and cellular microbiology ;
|v 22.
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1079/9781845939434.0000
|z View fulltext via EzAccess
|